S&P 500   3,327.77 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   3,327.77 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   3,327.77 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   3,327.77 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
Log in

NASDAQ:AFMDAffimed Stock Price, Forecast & News

$3.81
+0.08 (+2.14 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.64
Now: $3.81
$3.86
50-Day Range
$3.28
MA: $4.17
$4.73
52-Week Range
$1.42
Now: $3.81
$4.91
Volume850,869 shs
Average Volume1.18 million shs
Market Capitalization$290.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.72
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company's products include AFM24, an innate cell-engaging bispecific antibody that treats patients suffering of EGFR expressing solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; and Genentech. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Read More
Affimed logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AFMD
CUSIPN/A
Phone49-62-2167-4360

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.96 million
Book Value$0.57 per share

Profitability

Net Income$-36,250,000.00
Net Margins-280.35%

Miscellaneous

Employees8,406
Market Cap$290.47 million
Next Earnings Date8/11/2020 (Confirmed)
OptionableOptionable
$3.81
+0.08 (+2.14 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AFMD News and Ratings via Email

Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Affimed (NASDAQ:AFMD) Frequently Asked Questions

How has Affimed's stock been impacted by COVID-19 (Coronavirus)?

Affimed's stock was trading at $1.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AFMD shares have increased by 109.3% and is now trading at $3.81.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Affimed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Affimed
.

When is Affimed's next earnings date?

Affimed is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Affimed
.

How can I listen to Affimed's earnings call?

Affimed will be holding an earnings conference call on Tuesday, August 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Affimed's earnings last quarter?

Affimed NV (NASDAQ:AFMD) posted its earnings results on Tuesday, June, 23rd. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. The biopharmaceutical company earned $5.66 million during the quarter, compared to analyst estimates of $8.51 million. Affimed had a negative return on equity of 135.64% and a negative net margin of 280.35%.
View Affimed's earnings history
.

What price target have analysts set for AFMD?

1 brokers have issued 1 year price objectives for Affimed's stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Affimed's stock price to reach $8.00 in the next year. This suggests a possible upside of 110.0% from the stock's current price.
View analysts' price targets for Affimed
.

Has Affimed been receiving favorable news coverage?

News headlines about AFMD stock have been trending somewhat negative on Wednesday, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Affimed earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next several days.
View the latest news about Affimed
.

Who are some of Affimed's key competitors?

What other stocks do shareholders of Affimed own?

Who are Affimed's key executives?

Affimed's management team includes the following people:
  • Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 57)
  • Dr. Florian H. M. Fischer, MD, CFO & Member of Management Board (Age 51)
  • Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 55)
  • Prof. Melvyn Little, Founder & Consultant
  • Dr. Martin Treder, Chief Scientific Officer (Age 49)

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.58%), Russell Investments Group Ltd. (0.19%), Strs Ohio (0.11%), SG Americas Securities LLC (0.05%), Vigilare Wealth Management (0.04%) and ProShare Advisors LLC (0.03%).

Which major investors are selling Affimed stock?

AFMD stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Lindbrook Capital LLC.

Which major investors are buying Affimed stock?

AFMD stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Vigilare Wealth Management, First Quadrant L P CA, Diversified Trust Co, SG Americas Securities LLC, ProShare Advisors LLC, Strs Ohio, and Russell Investments Group Ltd..

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $3.81.

How big of a company is Affimed?

Affimed has a market capitalization of $290.47 million and generates $23.96 million in revenue each year. The biopharmaceutical company earns $-36,250,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Affimed employs 8,406 workers across the globe.

What is Affimed's official website?

The official website for Affimed is www.affimed.com.

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2167-4360 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.